STING1 and neoplasm: In BRCA1-deficient murine breast cancer models, this phenotypic reprogramming was mediated by the activation of the stimulator of interferon genes (STING) pathway, which is an established driver of enhanced anti-tumour immune responses upon CDK4/6 inhibition [129–131].